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ABSTRACT
Introduction The coronavirus (COVID-19) pandemic has 
caused significant global mortality and impacted lives around 
the world. Virus Watch aims to provide evidence on which 
public health approaches are most likely to be effective 
in reducing transmission and impact of the virus, and will 
investigate community incidence, symptom profiles and 
transmission of COVID-19 in relation to population movement 
and behaviours.
Methods and analysis Virus Watch is a household 
community cohort study of acute respiratory infections in 
England and Wales and will run from June 2020 to August 
2021. The study aims to recruit 50 000 people, including 
12 500 from minority ethnic backgrounds, for an online survey 
cohort and monthly antibody testing using home fingerprick 
test kits. Nested within this larger study will be a subcohort of 
10 000 individuals, including 3000 people from minority ethnic 
backgrounds. This cohort of 10 000 people will have full blood 
serology taken between October 2020 and January 2021 
and repeat serology between May 2021 and August 2021. 
Participants will also post self- administered nasal swabs 
for PCR assays of SARS- CoV-2 and will follow one of three 
different PCR testing schedules based on symptoms.
Ethics and dissemination This study has been approved 
by the Hampstead National Health Service (NHS) Health 
Research Authority Ethics Committee (ethics approval number 
20/HRA/2320). We are monitoring participant queries and 
using these to refine methodology where necessary, and are 
providing summaries and policy briefings of our preliminary 
findings to inform public health action by working through 
our partnerships with our study advisory group, Public Health 
England, NHS and government scientific advisory panels.
INTRODUCTION
The COVID-19 pandemic has caused millions 
of deaths and impacted lives around the 
world with the closure of schools, workplaces 
and limitations on freedom of movement. 
Vaccines and effective scalable treatments for 
COVID-19 have been developed and while 
these are rolled out across England and Wales 
we will need to rely on other measures to stop 
the spread of COVID-19. We will also require 
Strengths and limitations of this study
 ► Virus Watch is a large national household com-
munity cohort study of the occurrence of and risk 
factors for COVID-19 infection that aims to recruit 
50 000 people, including 12 500 from minority eth-
nic backgrounds.
 ► Virus Watch is designed to estimate the incidence of 
PCR- confirmed COVID-19 in those with respiratory 
and non- respiratory presentations and the incidence 
of hospitalisation among PCR- confirmed COVID-19 
cases.
 ► Virus Watch will measure effectiveness and im-
pact of recommended COVID-19 control measures 
including testing, isolation, respiratory and hand 
hygiene measures, and social distancing on risk of 
respiratory infection.
 ► Only households with a lead householder able to 
speak English are able to take part in the study. 
Participant information sheets and consent forms 
are available in 9 languages but the study surveys 
are in English, limiting participation for non- English 
speaking households.
 ► Only households of up to six people were eligible 
for inclusion and they are also required to have ac-
cess to an internet connection. These restrictions 
will limit the generalisability to large or multigener-
ational households, and those without access to the 
internet.
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studies to examine their long- term effectiveness as they 
are implemented across England and Wales.
Governments, including those of the UK devolved 
nations, are adopting a wide range of control measures 
to limit the spread of infection. These include isolation 
of people with COVID-19 symptoms and their household 
contacts, widespread testing and contact tracing, digital 
contact tracing using mobile phone apps, broad social 
distancing measures and local control measures. Environ-
mental cleaning, hand hygiene and face mask use are also 
advised.
Much of our current knowledge of COVID-19 comes 
from observations at the more severe end of the disease 
spectrum, in hospitalised patients and individuals who die 
having tested positive for the disease.1–3 Although large- 
scale studies of prevalence of PCR positive infection and 
seroprevalence have been established, there is currently 
limited information on symptom profiles through the 
course of illness in non- hospitalised populations, children, 
social and behavioural risk factors for infection, strength 
and duration of immunity, household and community 
transmission risk, and population behaviours during 
periods of wellness and illness (including social contacts, 
use of public spaces, testing behaviours, isolation, mask 
use, hand and respiratory hygiene). This information can 
only be gathered accurately through prospective large- 
scale community cohorts. Our experience of the Medical 
Research Council (MRC)/Wellcome Flu Watch study4 5 
and the Economic and Social Research Council (ESRC) 
Bug Watch6 study has allowed us to rapidly establish a 
national household cohort study of 50 000 individuals.
Virus Watch aims to provide evidence on which 
public health approaches are most likely to be effective 
in reducing the spread and impact of the virus and will 
investigate community incidence, symptom profiles and 
transmission of COVID-19 in relation to population 
movement and behaviour.
METHODS AND ANALYSIS
Study design and setting
Virus Watch is a household community cohort study 
of acute respiratory infections in England and Wales 
covering the second and potential subsequent waves 
of the COVID-19 pandemic. The study period will be 
from 1 June 2020 to 31 August 2021. The study aims 
to recruit 50 000 individuals, including 12 500 from 
minority ethnic backgrounds for an online survey 
cohort (study 1). Nested within this larger study will be 
a subcohort of 10 000 individuals (study 2), including 
3000 people from minority ethnic backgrounds. Partici-
pants in this laboratory subcohort will be selected based 
on their geographical distance from one of our blood- 
taking clinics; either a 10 km radius from a clinic in 
cities or a 20 km radius in rural areas. Participants will 
be balanced to be representative of the UK population 
for sex, age and region. Figure 1 provides an overview 
of the study design.
Households self- select into the study if they live in 
England or Wales and all members of a household need 
to consent to take part in the study to meet our inclusion 
criteria (online supplemental appendix 1). Households 
need to have an internet connection on a phone, tablet 
or computer, email, and at least one adult household 
member that can read English.A household is defined as 
one or more people (not necessarily related) whose usual 
residence (4 days/week or more) is at the same address. 
These householders share cooking facilities, a living room 
or sitting room or dining area.
Figure 1 Overview of cohort recruitment, PCR swabbing schedules and data collection for the Virus Watch household 
community cohort study.
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Primary outcomes
Study 1: online survey cohort
1. Incidence of respiratory infection symptoms, includ-
ing COVID-19 disease case definitions.
2. Effectiveness and impact of recommended COVID-19 
control measures including testing, isolation, social 
distancing, respiratory and hand hygiene measures on 
risk of respiratory infection.
3. Frequency of adherence to public health recommen-
dations for these control measures.
4. Proportion of community infections that result in hos-
pital admissions and death.
5. Vaccine effectiveness against asymptomatic and symp-
tomatic infections.
Study 2: laboratory testing subcohort
1. Incidence of PCR- confirmed COVID-19.
2. Incidence of PCR- confirmed COVID-19 in those with 
non- respiratory presentations.
3. Incidence of hospitalisation among PCR- confirmed 
COVID-19 cases.
4. Proportion of individuals with SARS- CoV-2 antibodies 
acquired through natural infection to pandemic coro-
navirus.
5. Proportion of individuals with cross- reacting antibod-
ies to seasonal coronaviruses acquiring (or not) SARS- 
CoV-2.
6. Household secondary attack rates.
7. Protective effect of antibodies on infection and re-
infection as well as the severity and spectrum of 
presentation.
Recruitment
We will use the Royal Mail Post Office Address File to 
generate a list of residential address lists from which 
households can be sampled and sent Virus Watch recruit-
ment postcards to. The proposed initial sample design is 
a single- stage stratified probability sample where implicit 
stratification is employed to benefit from the precision 
gains that stratified sampling can bring. Within each 
region, residential addresses are sorted by (A) quintiles of 
Index of Multiple Deprivation 2019, (B) within quintiles 
by local authorities, (C) postcodes, and (D) address. We 
will perform this in the nine government office regions of 
England as well as Wales (10 study regions in total).
We will assess recruitment rates and the representa-
tiveness of this initial sample following the mail out of 
50 000 postcards. If recruitment is lower than expected 
or under- representative of the national population, 
we will redesign our recruitment campaign to include 
a range of methods in order to build the cohort. This 
mixed recruitment strategy will be flexible and use a 
variety of methods including social media, study leaflet 
drops, text messaging, personalised letters and incentives. 
Social media adverts will be used to inform individuals 
about the study and direct them to our website, http:// 
ucl- virus- watch. net/, where they can read the participant 
information sheets and consent to taking part. Digital 
invitations will also be created for sharing via WhatsApp. 
Text messages and postal letters inviting patients from 
their general practitioner (GP) clinics will be organised 
via Local Clinical Research Networks.7 We will also work 
with trusted community partners and religious organisa-
tions to promote recruitment into the study.
In order for a household to be enrolled, they will require 
an internet connection (Wi- Fi, fixed or on a mobile 
phone), email address, and all household members 
must agree to take part. Households will nominate a lead 
householder who will submit study questionnaires. The 
lead householder will need to be able to read English 
to support other household members in survey comple-
tion. A household is defined as one or more people (not 
necessarily related) whose usual residence (4 days/week 
or more) is at the same address. These householders 
share cooking facilities, and may share a living room or 
sitting room or dining area if available. Households with 
more than six members will not be eligible for the study—
this criterion was set due to limitations of the Research 
Electronic Data Capture (REDCap) survey infrastructure 
which did not function correctly when attempting to work 
with household sizes of greater than six during our pilot 
testing of the survey.
Virus Watch is powered for our primary aims in study 
2 and the estimation of population- level symptomatic 
COVID-19 attack rate over time. Recruiting a cohort that 
is representative of the population is time consuming as 
it requires an initial invitation into a study followed by 
multiple follow- up contacts encouraging invited individ-
uals to register. Given the urgency of the public health 
situation to roll out our study as quickly as possible, we 
chose a different approach whereby we recruit a large 
cohort of 50 000 individuals and from within that cohort 
we select a subsample for the testing cohort (subcohort 
1) which is representative of the population in terms of 
age, sex, ethnicity, region, household size and propor-
tion of households with children. The larger cohort will 
be important in assessing rates and predictors of less 
frequent outcomes such as hospitalisation and death. 
Given recent information of marked ethnicity differences 
in mortality rates from COVID-19, we also chose to recruit 
an ethnicity sample designed to be sufficiently large to 
provide early indicators of whether these differential 
mortality rates are due to differences in disease incidence 
or in differences in severity or both.
Power analysis
The testing subcohort is powered for accurate weekly age- 
specific disease incidence rates to be measured assuming 
20%–30% clinical attack rate over 18 weeks. With a clinical 
attack rate of 30% of whom 20% need hospitalisation and 
0.5% die, we expect the following number of outcome 
events in our testing cohort of 10 000 individuals in study 
2: 3000 COVID-19 illnesses, 600 hospitalised cases and 15 
deaths. At 1 month into the outbreak we would be able 
to detect a 1.7- fold greater risk of disease in a population 
subgroup that constitutes one- fifth of the population, and 
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by 2 months the detectable relative risk would be only 1.2. 
At 1 month we could detect a 4% hospital admission rate 
among cases with 95% CI of 0.5 to 6.8, and by 2 months 
the CIs would narrow to 3.1 to 4.1. We have used estimates 
of the expected number of events over time to provide 
an indication of the fact that the cohort is sufficiently 
large to provide valuable information through the course 
of the pandemic. Sample size calculations have been 
informed by a realistic assessment of what we can achieve 
based on our previous experience.4 6 For the serology 
cohort of 3000 people from minority ethnic backgrounds 
we assume a modest design effect due to household and 
geographical clustering, and 500 participants for six 
different minority ethnic backgrounds would enable the 
measurement of a cumulative incidence of 10% with 95% 
CIs of 3% by each minority ethnic group.
Participant materials and incentives
Participant information sheets will be held on our study 
website (these along with consent forms were translated 
into six languages and a further three languages were 
added from December 2020). In order to participate, 
the whole household must take part. Each adult partic-
ipant will need to read through study information, and 
provide online informed consent for themselves and any 
children they are legally responsible for. Children aged 
6–9 and 10–15 years, respectively, will also be asked to 
read through age- specific study participant information 
sheets and provide online informed assent. For chil-
dren aged 5 and under, parents/guardians will consent 
on their behalf. Informed consent data will be securely 
stored in the University College London (UCL) Data Safe 
Haven which has been certified to the ISO27001 infor-
mation security standard and conforms to the National 
Health Service (NHS) Digital’s Data Security and Protec-
tion Toolkit. Local study teams will reconsent participants 
face to face, prior to undertaking blood sampling, and 
adult participants in study 2 will be offered a £10 voucher 
to reimburse travel costs, if required. From February 
2021, invitation letters sent by GP clinics will include a 
£20 voucher for households who agree to take part in the 
study.
Data collection and follow-up
Study 1: online survey cohort
The online survey cohort will collect data and follow up 
participants through six different sources. Survey data 
will be collected using REDCap electronic data capture 
tools hosted on the UCL Data Safe Haven (online supple-
mental appendices 2–4).8 REDCap is a secure, web- based 
application for research studies. The UCL Data Safe 
Haven provides a technical solution for storing, handling 
and analysing identifiable data. It has been certified to the 
ISO27001 information security standard and conforms to 
NHS Digital’s Data Security and Protection Toolkit .
1. Baseline survey. The lead householder will be asked to 
complete an online baseline survey for each member 
of their household. Information collected includes: 
demographics, occupation, income, ethnicity, country 
of birth, year of entry to UK, chronic medical condi-
tions, medications, pregnancy status, vaccines, mode 
of transport to work, any previous contact with some-
one with COVID-19, previous symptoms of COVID-19- 
like illness and infection prevention behaviours such 
as social distancing and hand hygiene.
2. Illness surveys. Participants will be followed up weekly 
via an email with a link to an illness survey. This is a 
weekly survey of the presence or absence of symptoms 
that could indicate COVID-19 disease including respi-
ratory, general infection or gastrointestinal symptoms. 
During illness, prospective daily symptom recording, 
quality of life, health- seeking behaviour (NHS 111, 
GP in person, GP by phone, accident and emergency, 
pharmacy, hospital), treatments and NHS investiga-
tions will be recorded. This survey will also include any 
respiratory and hand hygiene measures, self- isolation, 
activities and social contact, travel and face mask use. 
Questions around behavioural interventions, such as 
mask wearing and social distancing, aim to reflect the 
context and frequency/degree to which behaviours 
are practised according to governmental and public 
health guidelines and relevant scientific literature. 
The survey includes questions to the household on ac-
tivities undertaken in the week prior to symptom on-
set. The weekly survey will also be used to capture test 
results received from outside the study and requests 
to self- isolate, for example, via the UK Test- Trace- 
Isolate system. The weekly survey will also ask about 
participants’ COVID-19 vaccination uptake, including 
their date of vaccination, dose (ie, first or second) and 
which vaccine was administered.
3. Monthly surveys. A number of questions will be asked 
every month. The monthly surveys also provide flex-
ibility to ask additional questions (eg, behavioural 
changes) to reflect any new government directives on 
social distancing, testing, contact tracing and vaccine 
delivery. Core questions will also allow us to follow up 
reasons for any non- response in a given month (eg, 
because of illness, hospitalisation or holiday). We will 
also ask about online health information seeking, so-
cial distancing, including recent (week before) con-
tacts, activities, places visited and hand and respiratory 
hygiene. As with the weekly questionnaire, questions 
around behavioural practices will reflect governmental 
and public health guidelines and the scientific litera-
ture; monthly questionnaires will also investigate bar-
riers and enablers to health- related behaviours using 
purpose- developed questionnaires based on the Capa-
bility, Opportunity, Motivation, Behaviour model. We 
will also ask about finances, employment and mental 
health to see how the COVID-19 response is affecting 
participants’ well- being and ability to work. We will ask 
about access to healthcare for non- COVID-19 health 
problems to explore the indirect health impacts of the 
pandemic. We will ask about any COVID-19 PCR or an-
tibody test results performed outside the study and not 
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already reported through baseline surveys. We will ask 
about influenza vaccine uptake and COVID-19 vaccina-
tion intentions.
4. Data linkage. NHS Digital will undertake quarterly data 
linkage between cohort 1 and Hospital Episode Statis-
tics (HES), which includes admitted patient and criti-
cal care episodes, outpatient department bookings and 
emergency care contacts. This linkage will also include 
Office for National Statistics mortality data, COVID-19 
vaccination records and virology testing data routine-
ly collected by Public Health England (PHE), Public 
Health Wales and the Department of Health and So-
cial Care through ‘Pillar 1’ (testing in hospital patients 
and health and care workers) and ‘Pillar 2’ (commu-
nity testing). These data sources will be linked to the 
cohort using name, NHS numbers, dates of birth and 
postal address. Identifying variables will be removed 
before the linked data are transferred back to UCL 
for analysis. These data linkages will continue for up 
to 5 years after the end of the study as we anticipate 
COVID-19 will become a recurring winter infection 
and we wish to understand its impact on health ser-
vices in subsequent years. These linkage studies will 
identify any participants who have been admitted to 
hospital or died due to causes that could be directly or 
indirectly linked to the COVID-19 pandemic. Indirect 
causes include those related to limitations in health-
care access during the pandemic. Reductions in the 
use of routine health services will also be monitored 
via linkage to HES data.
5. Geolocation tracking. All adult participants will be 
asked about optional consent to use a secure geolo-
cation tracking app (Tracker for ArcGIS) installed on 
their mobile phone for the duration of the study.
6. Monthly antibody testing using home fingerprick kits. 
Adults aged 18 years and over enrolled in the online 
survey cohort, with the exception of those in laborato-
ry testing subcohort group 3, will be offered monthly 
antibody testing starting February 2021 and continu-
ing until the end of the study, using home fingerprick 
kits for self- collection of capillary blood samples. 
Those aged under 18 and living with adults enrolled 
in monthly antibody testing will continue completing 
online surveys. Monthly antibody testing (February–
August 2021) will use Conformitè Europëenne (CE)- 
marked at- home fingerprick kits designed to collect 
small- volume (400–600 μL) capillary blood samples. 
Samples are self- collected by adult participants and 
returned to a United Kindom Accreditation Service 
(UKAS)- accredited laboratory via prepaid post, where 
they will be tested for anti- nucleocapsid and anti- spike 
antibodies using validated electrochemiluminescence 
immunoassays.
Study 2: laboratory testing subcohort
All participants agreeing to take part in the main cohort 
(study 1) will be asked to provide consent to be contacted 
and invited to participate in one of the three laboratory 
testing subgroups. This will enable a cohort of 10 000 indi-
viduals selected from the main cohort of 50 000 individ-
uals to be maximally representative of the population of 
England and Wales. All participants taking part in study 2 
will be asked to use the national test, trace and isolation 
system in addition to providing samples as part of Virus 
Watch.
Study 2 will consist of three groups that will follow 
different schedules of antibody testing and nasal/throat 
swabs for PCR testing.
Group 1 (n=7000)
With data from this group we aim to identify infection in 
those with a wide range of respiratory symptoms. Partic-
ipants will be asked to submit a nose/throat swab if they 
experience 2 consecutive days of: fever (>37.8°C), feeling 
feverish, or new persistent cough, or loss or altered sense 
of smell or taste (COVID-19 suspected case definition), or 
shortness of breath, or ear pain or change in hearing, or 
sore throat, or sneezing, or blocked nose, or runny nose, 
or wheeze or sinus pain or congestion (other respiratory 
manifestations).
Group 2 (n=1000)
This group aims to identify the importance of non- 
respiratory presentations. Participants will be asked to 
submit a self- taken nasal/throat swab for PCR identifica-
tion of COVID-19 and other respiratory viruses if:
 ► Either 2 consecutive days of respiratory symptoms 
(eg, cough, runny nose, sneezing, shortness of breath, 
sore throat, blocked nose, sinus pain or congestion, 
ear pain or change in hearing, wheezing, loss of or 
altered sense of taste or sense of smell).
 ► Or 2 consecutive days of gastrointestinal symptoms 
(eg, diarrhoea/loose stools, abdominal pain, nausea 
or vomiting, loss of appetite).
 ► Or 2 consecutive days of general infection symptoms 
(eg, feeling feverish, having a high temperature, feel-
ings of severe unexplained tiredness, generalised 
muscle or joint aches).
Group 3 (n=2000)
This group aims to identify the extent of household trans-
mission. Participants will be asked to submit a nose/throat 
swab if they experience 2 consecutive days of cough or 
fever or loss of sense of taste or smell. Household contacts 
of the index case will also be asked to submit a swab on 
the same day whether or not they have symptoms.
If any of the swabs indicate SARS- CoV-2 infection, all 
household members will be asked to repeat the swab on 
day 7 and day 14. If there are no new SARS- CoV-2 cases 
in the household arising from swabs on days 7 and 14 
(assumed secondary cases) then all household members 
will be asked to undertake a home fingerprick antibody 
test on day 21. If there is one or more secondary cases in 
the household then the entire household will be asked to 
take an additional swab on day 21 and then undertake the 
fingerprick antibody tests on day 28.
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End of follow-up
Online participant follow- up will end in August 2021 for 
households enrolled in monthly antibody testing, and in 
May 2021 for others, although depending on the progres-
sion of COVID-19, we may ask participants to continue 
in the study for longer. Participants will be sent an exit 
survey. Participants will be contacted to arrange a second 
blood sample collection from April 2021. Follow- up 
through data linkage with HES, COVID-19 vaccination 
records and mortality data will continue for 5 years after 
the end of the study.
Laboratory testing
Antibody testing
Study 2 will be using two different types of antibody tests. 
First, full blood serology will be taken between October 
2020 and January 2021. We will use experienced health-
care professionals, including research nurses from the 
National Institute for Health Research Clinical Research 
Networks.7 Depending on local circumstances, visits to 
participants’ homes to take blood may also be arranged. 
Children aged 15 years or less can opt out of having their 
blood taken but will be offered a fingerprick antibody 
test conducted by a healthcare worker instead. All partici-
pants from laboratory group 3 will additionally be offered 
a fingerprick antibody test at the same time as blood 
taking. From April 2021 until July 2021, we will invite 
all participants back for full blood tests or, for children 
who do not wish to have a full bleed, healthcare worker- 
delivered fingerprick- based antibody tests.
Families of children who have not been able to attend 
for a blood test, or for a healthcare worker- delivered 
fingerprick antibody test, will be provided with postal kits 
to perform these at home. We also plan to use fingerprick 
antibody testing where local clinics are no longer able to 
undertake full blood tests due to COVID-19 travel restric-
tions. Extremely clinically vulnerable participants will 
be sent home fingerprick tests instead of being asked to 
provide a serological sample.
Virus detection
Participants will post swab samples for PCR assays of 
SARS- CoV-2, and subsequent testing for influenza virus, 
seasonal coronavirus, rhinovirus and respiratory syncytial 
virus. When SARS- CoV-2 is identified we will also under-
take whole- genome sequencing of the virus. Samples for 
COVID-19 diagnostics will be handled and processed 
according to the NHS and UCL guidance on sample 
handling during the COVID-19 pandemic.
COVID-19 PCR and serology results will be returned to 
participants via email message systems. These messages 
will include links to official support, information and 
advice from NHS and PHE as well as advice on how to 
interpret results based on current evidence. In laboratory 
group 3, where positive test results will trigger further 
testing of the household, the results email will also include 
details explaining the additional testing requests. We will 
be not asking for inconclusive PCR results to be repeated
Statistical analysis
Our primary analyses during the winter 2020/2021 
season will focus on estimating age- specific weekly rates of 
symptoms and risk factors for PCR- confirmed COVID-19 
illness and hospitalisation. For these analyses we will use 
Poisson regression models that account for clustering by 
household using robust SEs and we will explore the use 
of stratification or weighting of the sample by age and 
region as necessary to give nationally representative esti-
mates. Weekly rates will be expressed per 100 000 person- 
weeks for ease of comparison with national surveillance 
data.
We will examine the proportion of the population 
infected during the first wave (eg, February–September 
2020) and second and potential future pandemic 
waves. We will estimate the percentage of the popula-
tion infected by calculating age and wave- specific rates 
of serological infection and PCR- confirmed disease per 
100 person- seasons using Poisson regression with robust 
SEs to account for household- level clustering. A person- 
season will be defined by the epidemic curve in the cohort 
and therefore rates will account for differential follow- up 
time during each epidemic peak. In these analyses we will 
examine risk factors for infection, disease, disease severity 
and disease transmission.
We will estimate the proportion of serologically 
confirmed SARS- CoV-2 infections leading to symptomatic 
disease. First, we will calculate age- adjusted attributable 
rates of illness due to infection (subtracting rates of respi-
ratory illness in non- seroconverters from those in sero-
converters). Second, we will measure the proportion of 
seroconverters with PCR- confirmed COVID-19. Analyses 
plans will be developed prior to conducting all analyses.
We will estimate vaccine effectiveness against asymp-
tomatic SARS- CoV-2 infections and against symptomatic 
COVID-19 using anti- nucleocapsid seroconversion, posi-
tive PCR testing and self- reported symptom data. We will 
use both time- to- event and test- negative analytical frame-
works. Using quantitative antibody data, we will assess the 
dynamics of anti- spike antibodies over time and the rela-
tionship between antibody titres and the risk of infection.
While the study is being conducted, we will produce 
early, preliminary results and analyses for participants, 
the general public, government scientific advisory groups 
and policymakers in order to inform the public health 
response to the pandemic. These analyses will be reactive 
to the epidemiological circumstances and are therefore 
not defined in this protocol.
Modelling
We will build on our experience of working with PHE, 
Google and Microsoft to use anonymous national or subna-
tional aggregate web search engine data9 10 to monitor 
the spreading of the disease. We will use our study data 
as ground truth to train real- time disease prevalence esti-
mation algorithms. We will annotate Global Positioning 
System tracking data into standard categories including 
time at work and home, social venues, supermarkets, 
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hospitals, GPs and transport mode for incorporation in 
classical epidemiological analyses. Integrating the linked 
survey data, we will develop a predictive spatiotemporal 
transmission model to investigate the impact of various 
social distancing strategies.
Missing data
We have several strategies that attempt to address the 
issue of missing data. First, we have sought to minimise 
the amount and impact of missing data for key outcomes 
and exposures through the study design. For example, 
for a number of our primary outcomes (PCR- confirmed 
illness, hospitalisation and death) and exposures (vacci-
nation) we collect data both as self- reported and through 
data linkage with the relevant national data sets and regis-
tries. Second, we sought to minimise missing serological 
and Virus Watch specific swabbing outcomes in adults 
by making willingness to provide relevant specimens a 
prerequisite to study registration. Third, we know from 
our experience of previous community cohort studies 
of acute infections (Flu Watch4 and Bug Watch6) that 
response to weekly surveys (where our symptom data 
are collected) is high at around 75%, which we believe 
is achieved by keeping these weekly data collections 
simple and quick to complete. We have aimed to repli-
cate this approach in Virus Watch. Fourth, for important 
missing baseline demographic data (eg, age and sex) we 
have created follow- up surveys to try and collect missing 
data at a later point in time. Fifth, where necessary, we 
will address missing data in our analyses and use multiple 
imputation methods if appropriate.
Patient and public involvement
Due to the urgent nature of this study, we did not involve 
participants in its original design. We have previously 
conducted patient and public involvement to support 
similar community cohort studies of acute infections 
using similar methodologies. We have engaged the Young 
Persons Advisory Group for research at Great Ormond 
Street Hospital to provide feedback on our Children’s 
Participant Information Sheets. We have worked with the 
Race Equality Foundation and Doctors of the World in 
advising on the inclusion of people from minority ethnic 
backgrounds in Virus Watch and have set up an advisory 
group to inform the ongoing design and dissemination 
of health equity aspects of Virus Watch. They were not 
asked to assess the burden of the intervention and time 
required to participate in the research due to the urgent 
nature of setting the study up. This advisory group 
(consisting of lay members of the public, community 
leaders, charities and policy organisations who will be 
reimbursed for their time) will guide our health equity 
analyses and steer us on their implications for people, 
communities and policy. The advisory group will also 
help us prioritise what information and results to share, 
when and in what format.
ETHICS AND DISSEMINATION
This is a national study that has been approved by the 
Hampstead NHS Health Research Authority Ethics 
Committee (ethics approval number 20/HRA/2320). 
The study is compliant with the requirements of General 
Data Protection Regulation (2016/679) and the Data 
Protection Act (2018). All investigators and study site staff 
will comply with the requirements of the General Data 
Protection Regulation (2016/679) with regard to the 
collection, storage, processing and disclosure of personal 
information, and will uphold the Act’s core principles.
We will provide opportunities for survey participants 
to comment on survey methodology in the first monthly 
survey and consider revisions based on this. We are also 
monitoring participant queries through our study email 
address and using these to refine methodology where 
necessary.
Data sharing and access
We aim to share aggregate data from this project on 
our website and via a ‘Findings so far’ section on our 
website—https:// ucl- virus- watch. net/. We will also be 
sharing individual record- level data with personal iden-
tifiers removed on a research data- sharing service such 
as the Office for National Statistics Secure Research 
Service.11 In sharing the data we will work within the prin-
ciples set out in the UK Research and Innovation (UKRI) 
guidance on best practice in the management of research 
data.12 Access to use of the data while research is being 
conducted will be managed by the chief investigators (AH 
and RWA) in accordance with the principles set out in 
the UKRI guidance on best practice in the management 
of research data. It is the intention that the data arising 
from this research will initially be collected, cleaned and 
validated by the UCL research team and once this has 
been completed will be shared for wider use. We aim to 
make subsets of the data more rapidly available both on 
our study website and via the public- facing dashboard 
during the ongoing phase of data collection. In line with 
Principle 5 of the UKRI guidance on best practice in the 
management of research data, we plan to release data in 
batches as they become available or as updated results 
are published. Individual record data linked using NHS 
Digital will not be shared, only aggregated results. HES 
and mortality data may be obtained from a third party 
and are not publicly available. These data are owned by 
a third party and can be accessed by researchers applying 
to the Health and Social Care Information Centre for 
England. We will put analysis code on publicly available 
repositories to enable their reuse.
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